ECSP045208A - Aza-arilpiperazinas - Google Patents

Aza-arilpiperazinas

Info

Publication number
ECSP045208A
ECSP045208A EC2004005208A ECSP045208A ECSP045208A EC SP045208 A ECSP045208 A EC SP045208A EC 2004005208 A EC2004005208 A EC 2004005208A EC SP045208 A ECSP045208 A EC SP045208A EC SP045208 A ECSP045208 A EC SP045208A
Authority
EC
Ecuador
Prior art keywords
disorders
nervous system
central nervous
arilpiperazinas
aza
Prior art date
Application number
EC2004005208A
Other languages
English (en)
Inventor
David Reginald Adams
Jonathan Mark Bentley
Toby Jonathan Blench
Paul Hebeisen
Nathaniel Julius Thomas Monck
Hans Richter
Stephan Roever
Jonathan Richard Anthony Roffey
Sven Taylor
Original Assignee
Hoffmann La Roche
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Vernalis Res Ltd filed Critical Hoffmann La Roche
Publication of ECSP045208A publication Critical patent/ECSP045208A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Reproductive Health (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gynecology & Obstetrics (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Epoxy Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

La presente invención se refiere a compuestos químicos de la fórmula (I)así como a sales, solvatos y ésteres farmacéuticamente aceptables de los mismos, en la que de R1 a R4 tienen los significados definidos en la reivindicación 1. Pueden utilizarse en forma de preparados farmacéuticos para el tratamiento o prevención de trastornos del sistema nervioso central, lesiones del sistema nervioso central, trastornos cardiovasculares, trastornos gastrointestinales, diabetes, obesidad y apnea nocturna.
EC2004005208A 2002-01-29 2004-07-27 Aza-arilpiperazinas ECSP045208A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0202015.4A GB0202015D0 (en) 2002-01-29 2002-01-29 Piperazine Derivatives

Publications (1)

Publication Number Publication Date
ECSP045208A true ECSP045208A (es) 2004-09-28

Family

ID=9929954

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2004005208A ECSP045208A (es) 2002-01-29 2004-07-27 Aza-arilpiperazinas

Country Status (33)

Country Link
US (1) US7098337B2 (es)
EP (1) EP1472255B1 (es)
JP (1) JP4213042B2 (es)
KR (1) KR100644004B1 (es)
CN (1) CN1290847C (es)
AR (1) AR038237A1 (es)
AT (1) ATE318817T1 (es)
AU (1) AU2003205622B2 (es)
BR (1) BR0307291A (es)
CA (1) CA2472954C (es)
DE (1) DE60303791T2 (es)
DK (1) DK1472255T3 (es)
EA (1) EA200400881A1 (es)
EC (1) ECSP045208A (es)
ES (1) ES2259757T3 (es)
GB (1) GB0202015D0 (es)
GT (1) GT200300015A (es)
HR (1) HRP20040653A2 (es)
IL (1) IL162727A0 (es)
MA (1) MA27097A1 (es)
MX (1) MXPA04007147A (es)
NO (1) NO20043547L (es)
PA (1) PA8564001A1 (es)
PE (1) PE20030847A1 (es)
PL (1) PL371922A1 (es)
PT (1) PT1472255E (es)
RS (1) RS65704A (es)
SI (1) SI1472255T1 (es)
TN (1) TNSN04136A1 (es)
TW (1) TW200307683A (es)
UY (1) UY27627A1 (es)
WO (1) WO2003064423A1 (es)
ZA (1) ZA200405458B (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA05012547A (es) * 2003-05-21 2006-05-25 Prosidion Ltd Inhibidores de amida de acido pirrolopiridina-2-carboxilico de fosforilasa de glucogeno.
US7405210B2 (en) 2003-05-21 2008-07-29 Osi Pharmaceuticals, Inc. Pyrrolopyridine-2-carboxylic acid amide inhibitors of glycogen phosphorylase
GB0314967D0 (en) * 2003-06-26 2003-07-30 Hoffmann La Roche Piperazine derivatives
TW200528102A (en) * 2003-10-24 2005-09-01 Solvay Pharm Gmbh Novel medical combination treatment of obesity involving 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
WO2005039579A1 (en) * 2003-10-24 2005-05-06 Solvay Pharmaceuticals Gmbh Combination treatment of obesity involving selective cb1-antagonists and lipase inhibitors
EP2248524A3 (en) 2004-08-25 2011-03-09 Takeda Pharmaceutical Company Limited Preventives/remedies for stress urinary incontinence and method of screening the same
AU2005298692A1 (en) 2004-10-25 2006-05-04 Solvay Pharmaceuticals Gmbh Pharmaceutical compositions comprising CB1 cannabinoid receptor antagonists and potassium channel openers for the treatment of diabetes mellitus type I, obesity and related conditions
ATE514698T1 (de) 2005-05-03 2011-07-15 Hoffmann La Roche Tetracyclische azapyrazinoindoline als 5-ht2- liganden
WO2006125179A1 (en) * 2005-05-19 2006-11-23 Xenon Pharmaceuticals Inc. Tricyclic compounds and their uses as therapeutic agents
ES2351940T3 (es) * 2005-11-18 2011-02-14 F. Hoffmann-La Roche Ag Derivados de azaindol-2-carboxamida.
JP2009518351A (ja) 2005-12-09 2009-05-07 エフ．ホフマン−ラ ロシュ アーゲー 肥満症の処置に有用な三環性アミド誘導体
BRPI0619985A2 (pt) 2005-12-16 2011-10-25 Hoffmann La Roche compostos, processo para a sua manufatura, composições farmacêuticas, métodos para o tratamento e/ou prevenção de enfermidades que estão associadas com a modulação de receptores de h3, de obesidade e de diabetes do tipo ii em um ser humano ou animal e usos dos compostos
EP2742936A1 (en) 2006-05-16 2014-06-18 Takeda Pharmaceutical Company Limited Fused heterocyclic compound and use thereof
JP2010500300A (ja) 2006-08-08 2010-01-07 サノフィ−アベンティス アリールアミノアリール−アルキル−置換イミダゾリジン−２，４−ジオン、それらの製造法、それらの化合物を含有する薬剤、およびそれらの使用
EP2789338A3 (en) 2007-11-15 2015-01-14 Takeda Pharmaceutical Company Limited Condensed pyridine derivate and use thereof
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
MX2012001729A (es) 2009-08-26 2012-06-13 Sanofi Sa Nuevos hidratos cristalinos de fluoroglicosido heteroaromatico, productos farmaceuticos que comprenden estos compuestos, y su empleo.
JPWO2011071136A1 (ja) 2009-12-11 2013-04-22 アステラス製薬株式会社 線維筋痛症治療剤
FR2960876B1 (fr) * 2010-06-03 2012-07-27 Sanofi Aventis Derives de 3,4-dihydropyrrolo[1,2-a]pyrazine-2,8(1h)-dicarboxamide leur preparation et leur application en therapeutique.
EP2683702B1 (de) 2011-03-08 2014-12-24 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683701B1 (de) 2011-03-08 2014-12-24 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8828995B2 (en) 2011-03-08 2014-09-09 Sanofi Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
EP2683698B1 (de) 2011-03-08 2017-10-04 Sanofi Mit adamantan- oder noradamantan substituierte benzyl-oxathiazinderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683705B1 (de) 2011-03-08 2015-04-22 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120052A1 (de) 2011-03-08 2012-09-13 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8895547B2 (en) 2011-03-08 2014-11-25 Sanofi Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
EP2841417A1 (en) * 2012-04-26 2015-03-04 Francis Xavier Tavares Synthesis of lactams
CN104540829B (zh) * 2012-08-06 2017-04-26 霍夫曼-拉罗奇有限公司 哌嗪并[1,2‑a]吲哚‑1‑酮和[1,4]二氮杂*并[1,2‑a]吲哚‑1‑酮
WO2015066344A1 (en) 2013-11-01 2015-05-07 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
WO2018035477A1 (en) * 2016-08-19 2018-02-22 Arena Pharmaceuticals, Inc. 5-ht2c receptor agonists and compositions and methods of use
EP3733204A4 (en) 2017-12-27 2021-09-15 Takeda Pharmaceutical Company Limited THERAPEUTIC AGENT FOR URINARY INCONTINENCE OF STRESS AND FECAL INCONTINENCE

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) * 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) * 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) * 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
PT1105123E (pt) 1998-08-14 2004-08-31 Hoffmann La Roche Composicoes farmaceuticas contendo inibidores da lipase e quitosano
TR200100471T2 (tr) 1998-08-14 2001-07-23 F.Hoffmann-La Roche Ag Lipaz inhibitörleri içeren farmasötik bileşimler
GB9902047D0 (en) * 1999-01-29 1999-03-17 Cerebrus Ltd Chemical compounds XI
FR2799757B1 (fr) * 1999-10-15 2001-12-14 Adir Nouveaux derives polycycliques azaindoliques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent

Also Published As

Publication number Publication date
TNSN04136A1 (en) 2007-03-12
GT200300015A (es) 2003-09-12
PT1472255E (pt) 2006-06-30
EP1472255A1 (en) 2004-11-03
JP4213042B2 (ja) 2009-01-21
ES2259757T3 (es) 2006-10-16
US20030207888A1 (en) 2003-11-06
NO20043547L (no) 2004-08-25
MXPA04007147A (es) 2004-10-29
PE20030847A1 (es) 2003-10-21
CA2472954C (en) 2009-04-28
EP1472255B1 (en) 2006-03-01
IL162727A0 (en) 2005-11-20
GB0202015D0 (en) 2002-03-13
JP2005521671A (ja) 2005-07-21
DE60303791D1 (en) 2006-04-27
CN1290847C (zh) 2006-12-20
TW200307683A (en) 2003-12-16
PL371922A1 (en) 2005-07-11
AU2003205622B2 (en) 2006-10-19
DE60303791T2 (de) 2006-11-02
WO2003064423A1 (en) 2003-08-07
KR20040077885A (ko) 2004-09-07
ATE318817T1 (de) 2006-03-15
KR100644004B1 (ko) 2006-11-10
DK1472255T3 (da) 2006-07-10
SI1472255T1 (sl) 2006-06-30
MA27097A1 (fr) 2004-12-20
CA2472954A1 (en) 2003-08-07
RS65704A (sr) 2006-10-27
CN1625558A (zh) 2005-06-08
AR038237A1 (es) 2005-01-05
ZA200405458B (en) 2006-02-22
UY27627A1 (es) 2003-07-31
HRP20040653A2 (hr) 2005-06-30
PA8564001A1 (es) 2003-09-05
BR0307291A (pt) 2004-12-07
EA200400881A1 (ru) 2005-02-24
US7098337B2 (en) 2006-08-29

Similar Documents

Publication Publication Date Title
ECSP045208A (es) Aza-arilpiperazinas
UY26863A1 (es) Derivados de la piperazina
PA8534801A1 (es) Derivados de piperazina
UY27097A1 (es) Derivados del indol
UY27204A1 (es) Derivados de pieracina
UY27300A1 (es) Nuevos derivados de quinolina
UY27646A1 (es) Derivados de quinolina como antagonistas de npt
GT200100183A (es) Derivados de quinolina y quinazolina.
AR020662A1 (es) Compuestos dihidrotiazoles policiclicos, procedimientos para su preparacion, medicamento, procedimiento para la preparacion de dicho medicamento y lautilizacion de dichos compuestos para la preparacion de un medicamento.
PA8555401A1 (es) Derivados de quinolina
IS8485A (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
EA200901373A1 (ru) Аминогетероциклические соединения
WO2010030781A3 (en) Aromatic carboxylic acid derivatives for treatment and prophylaxis of gastrointestinal diseases including colon cancer
NO20073830L (no) Medikamenter for behandling eller forebygging av fibrotiske sykdommer
ATE538666T1 (de) Nahrungsergänzung zur verhinderung von abmagerungen
ECSP088572A (es) Nuevos compuestos
UY27018A1 (es) Derivados de la pirimidina
GEP20094854B (en) Compounds for treating diseases of impaired gastric motility
CL2008003232A1 (es) Compuestos derivados de bencensulfonanilida; composición farmacéutica que los comprende; y uso en el tratamiento de enfermedades del sistema nervioso central, disfunciones cognitivas, esquizofrenia, enfermedades adictivas, enfermedad de alzheimer u obesidad.
DE60300683D1 (de) Prucaloprid-n-oxid
BRPI0415428A (pt) formulações terapêuticas
PA8535701A1 (es) Derivados del indol
GT200100262A (es) Derivados de indol.
TH98274A (th) สารปรับคุมแคนนาบินอยด์ รีเซปเตอร์
TH106997A (th) อนุพันธ์ควินาโซลีน-2,4-ไดโอนใหม่และองค์ประกอบทางเภสัชกรรมสำหรับการป้องกันหรือการรักษาของโรคสมองทางประสาทวิทยา